<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Multiple myeloma: Initial treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Multiple myeloma: Initial treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Multiple myeloma: Initial treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jacob P Laubach, MD, MPP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">S Vincent Rajkumar, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 31, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Multiple myeloma (MM) is a plasma cell neoplasm characterized by clonal plasma cells that produce a monoclonal immunoglobulin. These plasma cells proliferate in the bone marrow and can result in extensive skeletal destruction with osteolytic lesions, osteopenia, and/or pathologic fractures. Additional disease-related complications include hypercalcemia, kidney impairment, anemia, and infections. Treatment directed at the underlying plasma cell clone is required to prevent complications and improve overall survival. </p><p>MM must be distinguished from the premalignant stages of myeloma, namely monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)  (<a class="graphic graphic_table graphicRef57627" href="/d/graphic/57627.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef94388" href="/d/graphic/94388.html" rel="external">algorithm 1</a>). In contrast to MM, active treatment is not routinely indicated for patients with MGUS or SMM. (See  <a class="medical medical_review" href="/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"</a>.)</p><p>The initial chemotherapy for patients with MM treated in resource-rich settings is discussed here. Other aspects of care are discussed separately, including chemotherapy options for patients in resource-poor settings, a general management overview, details regarding the use and timing of autologous hematopoietic cell transplantation, and response assessment.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6650.html" rel="external">"Multiple myeloma: Management in resource-limited settings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation"</a>.)</p><p></p><p>Separate discussions are also available regarding the administration of common therapies, the use of osteoclast inhibitors, thromboprophylaxis for patients receiving immunomodulatory agents, and the treatment of relapsed or resistant MM.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6663.html" rel="external">"Multiple myeloma: The use of osteoclast inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/121127.html" rel="external">"Multiple myeloma: Treatment of first or second relapse"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/131449.html" rel="external">"Multiple myeloma: Treatment of third or later relapse"</a>.)</p><p></p><p class="headingAnchor" id="H2981408068"><span class="h1">GOALS OF THERAPY</span><span class="headingEndMark"> — </span>Patients with MM are not cured with conventional therapy. Treatment alleviates symptoms, reverses cytopenias, and decreases end-organ damage, and is given with the overall goals of achieving and maintaining a response, improving quality of life, and prolonging overall survival.</p><p class="headingAnchor" id="H3858522963"><span class="h1">CHOICE OF THERAPY</span></p><p class="headingAnchor" id="H1942797941"><span class="h2">Risk-stratified treatment</span></p><p class="headingAnchor" id="H1805504075"><span class="h3">Risk stratification and other factors impacting choice</span><span class="headingEndMark"> — </span>Patients with MM can be categorized as having standard-risk or high-risk disease based on the results of fluorescence in situ hybridization (FISH) for specific translocations and/or deletions and certain other tests  (<a class="graphic graphic_table graphicRef78344" data-inline-graphics="78344" href="/d/graphic/78344.html" rel="external">table 2</a>). This risk stratification has considerable prognostic value and helps guide the selection of initial therapy  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>). Risk stratification is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management", section on 'Risk stratification'</a>.)</p><p>The choice among treatment regimens should also take into consideration the patient's: </p><p class="bulletIndent1"><span class="glyph">●</span>Age</p><p class="bulletIndent1"><span class="glyph">●</span>Performance status</p><p class="bulletIndent1"><span class="glyph">●</span>Comorbid conditions</p><p class="bulletIndent1"><span class="glyph">●</span>Preferences regarding the type of treatment they receive</p><p class="bulletIndent1"><span class="glyph">●</span>Potential for chemotherapy-related side effects</p><p></p><p>All patients should be evaluated for supportive care and use of prophylaxis to minimize complications. (See <a class="local">'Prevention and management of complications'</a> below.) </p><p>Although historically the regimens used as induction therapy for transplant-eligible patients differed significantly from those used for patients who are not eligible for transplant, that is no longer the case, particularly as melphalan-based regimens are rarely used for transplant-ineligible patients whereas they were widely used in the past. </p><p>Many of the preferred treatment options have not been compared directly with each other in a randomized trial in these patient populations. As such, there is no standard of care and different experts use different regimens. Data supporting their use come largely from single-arm trials or randomized trials comparing these regimens with other regimens. Three-drug regimens are preferred over two-drug regimens whenever possible because they appear to provide an overall survival (OS) benefit. Four-drug regimens may offer additional benefits. </p><p>Our approach is generally consistent with that proposed by the International Myeloma Working Group [<a href="#rid1">1-7</a>]. Links to guidelines are provided separately. (See <a class="local">'Society guideline links'</a> below.)</p><p class="headingAnchor" id="H376980116"><span class="h3">Standard-risk myeloma</span><span class="headingEndMark"> — </span>For patients with standard-risk MM  (<a class="graphic graphic_table graphicRef78344" href="/d/graphic/78344.html" rel="external">table 2</a>), three-drug regimens are preferred over two-drug regimens because randomized trials have shown that they improve OS  (<a class="graphic graphic_algorithm graphicRef97453" data-inline-graphics="97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>). When compared with three-drug regimens, initial trial results also suggest that four-drug regimens deepen response and improve progression-free survival (PFS), albeit with an increase in toxicity and cost. As such, a choice between three-drug and four-drug regimens is largely driven by patient values, preferences, and access. Those who prioritize PFS may reasonably select a four-drug regimen. Three-drug regimens remain an acceptable option for patients with standard-risk MM who prioritize avoiding the costs and toxicity of adding a fourth drug.  </p><p>Our preferred regimens for standard-risk MM include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">Daratumumab</a>, <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (DVRd) is a reasonable option for patients who prioritize PFS and are willing to accept the increased toxicity and cost. When compared with bortezomib, lenalidomide, and dexamethasone (VRd), DVRd deepens responses and improves PFS [<a href="#rid8">8-10</a>]. (See <a class="local">'Daratumumab, bortezomib, lenalidomide, dexamethasone'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">Bortezomib</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (VRd)  (<a class="graphic graphic_table graphicRef91054" href="/d/graphic/91054.html" rel="external">table 3</a>) is a reasonable option for those who prioritize avoiding the costs and toxicity of adding a fourth drug. A randomized phase 3 trial demonstrated superior OS with VRd when compared with lenalidomide plus dexamethasone (Rd)  (<a class="graphic graphic_table graphicRef56451" href="/d/graphic/56451.html" rel="external">table 4</a>) [<a href="#rid11">11</a>]. (See <a class="local">'Bortezomib, lenalidomide, dexamethasone'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">Daratumumab</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (DRd)  (<a class="graphic graphic_table graphicRef119710" href="/d/graphic/119710.html" rel="external">table 5</a>) is an alternative, especially for patients who may not tolerate <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> (eg, those with pre-existing neuropathy). DRd has shown improved OS when compared with Rd and is associated with minimal peripheral neuropathy [<a href="#rid12">12</a>]. (See <a class="local">'Daratumumab, lenalidomide, dexamethasone'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">Bortezomib</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (VCd; also called CyBorD)  (<a class="graphic graphic_table graphicRef50061" href="/d/graphic/50061.html" rel="external">table 6</a>) is effective for patients with significant kidney impairment related to myeloma or other factors, and there is minimal thromboembolic risk associated with this combination. It is an important option in countries where <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> is not approved for initial therapy [<a href="#rid13">13</a>]. (See <a class="local">'Bortezomib, cyclophosphamide, dexamethasone'</a> below and <a class="local">'Acute kidney failure'</a> below.)</p><p></p><p>Patients who are eligible for autologous hematopoietic cell transplantation (HCT) are typically treated with three to six cycles of induction therapy followed by autologous stem cell collection. Then a decision is made regarding whether to proceed with autologous HCT (early HCT strategy) or continue the same chemotherapy regimen, reserving HCT for first relapse (delayed HCT strategy). (See <a class="local">'Incorporating HCT in eligible patients'</a> below.)</p><p>The total number of cycles used for an individual patient depends on whether the patient plans to proceed immediately with HCT, how well they tolerate the regimen, and the response to treatment. Those not proceeding to early HCT are typically treated with 8 to 12 cycles, as tolerated, followed by maintenance until progression. Choice of maintenance regimen is discussed in more detail separately. (See <a class="local">'Maintenance for patients who are ineligible for or defer HCT'</a> below.)</p><p class="headingAnchor" id="H843435329"><span class="h3">High-risk myeloma</span><span class="headingEndMark"> — </span>Patients with high-risk MM  (<a class="graphic graphic_table graphicRef78344" href="/d/graphic/78344.html" rel="external">table 2</a>) should be encouraged to participate in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=6647" target="_blank">clinical trials</a> and should be considered for novel therapeutic strategies, since they tend to do less well with conventional treatment options. Outside of a clinical trial, we suggest initial treatment with a proteasome inhibitor-containing regimen and/or daratumumab-containing regimen. This preference is based on limited data that suggest use of these agents may abrogate the prognostic impact of at least some of these high-risk genetic markers [<a href="#rid14">14-19</a>]. </p><p>Our preferred regimen depends on whether the patient is a candidate for autologous HCT and comorbidities  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>HCT ineligible</strong> – For patients with high-risk MM who are ineligible for HCT, we administer 8 to 12 cycles of a three-drug regimen that includes a proteasome inhibitor or <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">daratumumab</a>, followed by maintenance until progression  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients, we prefer VRd  (<a class="graphic graphic_table graphicRef91054" href="/d/graphic/91054.html" rel="external">table 3</a>) or DRd  (<a class="graphic graphic_table graphicRef119710" href="/d/graphic/119710.html" rel="external">table 5</a>) as these combinations have demonstrated an OS benefit over Rd alone [<a href="#rid11">11,12</a>]. (See <a class="local">'Bortezomib, lenalidomide, dexamethasone'</a> below and <a class="local">'Daratumumab, lenalidomide, dexamethasone'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>VCd  (<a class="graphic graphic_table graphicRef50061" href="/d/graphic/50061.html" rel="external">table 6</a>) is an acceptable alternative for patients at higher risk of complications with <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> (eg, acute kidney failure, increased thromboembolic risk) and for those in countries in which lenalidomide is not approved for initial therapy [<a href="#rid13">13</a>]. (See <a class="local">'Bortezomib, cyclophosphamide, dexamethasone'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HCT eligible</strong> – For patients with high-risk MM who are candidates for autologous HCT, we administer three to six cycles of a four-drug regimen that contains a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, typically DVRd. (See <a class="local">'Daratumumab, bortezomib, lenalidomide, dexamethasone'</a> below.)</p><p></p><p class="bulletIndent1">We then collect stem cells and proceed with HCT, followed by two-agent maintenance until progression  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>). This preference for early HCT and the choice between single or double HCT is discussed separately. (See  <a class="medical medical_review" href="/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Early versus late HCT'</a> and  <a class="medical medical_review" href="/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Tandem HCT and/or consolidation'</a>.)</p><p></p><p class="bulletIndent1">As described in more detail below, the addition of <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">daratumumab</a> to VRd deepens responses and improves PFS. (See <a class="local">'Daratumumab, bortezomib, lenalidomide, dexamethasone'</a> below.)</p><p></p><p class="bulletIndent1">In addition, limited data suggest that the prognostic impact of at least some of these high-risk genetic markers may be abrogated by the use of a proteasome inhibitor and/or an anti-CD38 monoclonal antibody. As an example, several trials of proteasome inhibitor-containing regimens suggested that outcomes in patients with high-risk MM, while expected to be worse, were similar to those of standard-risk MM, although the number of patients with high-risk MM was small [<a href="#rid14">14,19,20</a>]. In addition, a meta-analysis of patients with high-risk MM included in six phase 3 trials reported a PFS benefit when <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">daratumumab</a> was added to initial therapy (hazard ratio [HR] 0.67, 95% CI 0.47-0.95) or subsequent therapy (HR 0.45, 95% CI 0.30-0.67) [<a href="#rid15">15</a>]. </p><p></p><p class="headingAnchor" id="H2804262284"><span class="h2">Special populations</span><span class="headingEndMark"> — </span>The general treatment principles described above apply to most treatment settings and patient populations. However, patients with kidney failure, frail adults, and patients being treated in resource-poor settings require special consideration.</p><p class="headingAnchor" id="H1800104552"><span class="h3">Acute kidney failure</span><span class="headingEndMark"> — </span>In patients with acute kidney failure due to cast nephropathy, regimens that act rapidly and can be used safely without major dose adjustment are preferred. <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> is typically avoided. </p><p>VCd, also known as CyBorD, and <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (VTd) are two primary options, and the choice between the two is based on experience with the regimen and drug availability; in the United States, VCd is more widely used than VTd. Our approach to patients with this presentation is discussed separately. (See  <a class="medical medical_review" href="/d/html/7211.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Treatment and prognosis", section on 'Overview of approach'</a>.)</p><p class="headingAnchor" id="H2859612190"><span class="h3">Frail adults</span><span class="headingEndMark"> — </span>Frail adults are often older patients with comorbidities and limited ability to perform instrumental and standard activities of daily living who experience higher rates of treatment discontinuation due to toxicity, and inferior PFS and OS [<a href="#rid21">21-26</a>]. Older adults may benefit from a more formal comprehensive geriatric assessment to assess frailty. (See  <a class="medical medical_review" href="/d/html/2808.html" rel="external">"Comprehensive geriatric assessment for patients with cancer"</a>.)</p><p>Dose modifications are needed in this population. For all of the regimens discussed below, we advise that the dose of <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> be decreased to 15 mg (instead of 25 mg), and in some cases to 10 mg (eg, in the setting of kidney dysfunction), and the dose of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> to 20 mg once a week (instead of 40 mg once a week). For patients who attain a good response after 9 to 12 months of a regimen that includes lenalidomide plus dexamethasone, we discontinue dexamethasone, and continue lenalidomide alone rather than both drugs as maintenance. Support for this transition is discussed separately. (See <a class="local">'Lenalidomide plus dexamethasone'</a> below.)</p><p>The choice of initial regimen should take into account tolerability and convenience  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Rd  (<a class="graphic graphic_table graphicRef56451" href="/d/graphic/56451.html" rel="external">table 4</a>) is an effective oral regimen and is our preferred option for frail patients with standard-risk MM unable to tolerate a three-drug regimen. (See <a class="local">'Lenalidomide plus dexamethasone'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VRd  (<a class="graphic graphic_table graphicRef91054" href="/d/graphic/91054.html" rel="external">table 3</a>) is a three-drug option, especially for patients with high-risk MM, that can be given at a modified dose and schedule to enhance tolerability in this population [<a href="#rid27">27</a>]. If tolerated, VRd improves OS over that seen with Rd alone [<a href="#rid11">11</a>]. (See <a class="local">'Bortezomib, lenalidomide, dexamethasone'</a> below and <a class="local">'High-risk myeloma'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DRd  (<a class="graphic graphic_table graphicRef119710" href="/d/graphic/119710.html" rel="external">table 5</a>) is another important three-drug option, which was associated with an OS advantage over that seen with Rd alone [<a href="#rid12">12</a>]. (See <a class="local">'Daratumumab, lenalidomide, dexamethasone'</a> below.) </p><p></p><p>While response rates mirror those in other populations, the main challenge is treatment discontinuation and/or early mortality due to toxicity. In a phase 2 trial (HOVON 143) of <a class="drug drug_general" data-topicid="105607" href="/d/drug information/105607.html" rel="external">ixazomib</a>, <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">daratumumab</a>, plus <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> in frail patients with newly diagnosed MM, one-half were unable to complete the planned induction therapy [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H679700021"><span class="h3">Resource-limited settings</span><span class="headingEndMark"> — </span>Newer agents for the treatment of MM are not routinely available in many countries due to the lack of regulatory approval or due to high cost. In these settings, the choice of initial therapy should consider alternative regimens. These include several melphalan-based regimens and thalidomide-based regimens. These are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/6650.html" rel="external">"Multiple myeloma: Management in resource-limited settings"</a>.)</p><p class="headingAnchor" id="H1790247036"><span class="h1">COORDINATING CARE</span></p><p class="headingAnchor" id="H3819285960"><span class="h2">Incorporating HCT in eligible patients</span><span class="headingEndMark"> — </span>High-dose chemotherapy followed by autologous hematopoietic cell transplantation (HCT; rescue) is a standard of care for eligible patients with newly diagnosed MM. As such, all patients with MM should be assessed at the time of diagnosis to determine whether they are eligible for autologous HCT, and the initial chemotherapy given to patients who are candidates for HCT should avoid agents that may damage stem cells (eg, <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a>). (See  <a class="medical medical_review" href="/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management", section on 'Determine transplant eligibility'</a>.)</p><p>Patients who are eligible for HCT are typically treated with three to six cycles of induction therapy followed by autologous stem cell collection  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>). Then a decision is made regarding whether to proceed with autologous HCT (early HCT strategy) or continue the same chemotherapy regimen reserving HCT for first relapse (delayed HCT strategy). Both approaches so far have produced similar overall survival (OS) rates, with the incorporation of HCT associated with longer duration of progression-free survival (PFS). </p><p>Whether to pursue an early versus delayed HCT strategy depends on clinical features and risk stratification, response to induction therapy, and patient preferences regarding the timing of transplant. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Early versus late HCT'</a>.)</p><p class="headingAnchor" id="H1911347096"><span class="h2">Maintenance for patients who are ineligible for or defer HCT</span><span class="headingEndMark"> — </span>There is ongoing debate regarding the role of maintenance therapy in patients with MM who are ineligible for or defer autologous HCT and experts differ in their approach. We suggest maintenance therapy for most patients; this preference places a high value on delaying progression and the potential for an as yet unproven OS benefit and places a lower value on the risks associated with continued therapy. </p><p>Our preferred maintenance depends on risk stratification and comorbidities  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>). The risk of second cancers must be discussed with all patients who are treated with <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> maintenance [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Immunomodulatory drugs'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>High-risk MM – Following 8 to 12 cycles of triplet or quadruplet induction therapy, we offer patients with high-risk MM two-agent maintenance until time of disease progression. For those initially treated with DVRd or VRd, we offer maintenance with both <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>. For those initially treated with DRd, we offer maintenance with both lenalidomide and <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">daratumumab</a>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Standard-risk MM – Following 8 to 12 cycles of triplet therapy, we offer patients with standard-risk MM maintenance with single-agent <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> until progression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Frail patients – Following 8 to 12 cycles of treatment with modified triplet therapy or <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> plus <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (Rd), we offer frail patients with standard-risk MM maintenance with single-agent lenalidomide until progression. (See <a class="local">'Frail adults'</a> above.)</p><p></p><p>The rationale for maintenance therapy in MM includes the incurability of MM and recognition that relapse may present acutely with life-threatening complications. Prospective trials suggest that maintenance therapy prolongs PFS, but data are mixed as to whether there is meaningful improvement in OS. Additional support for maintenance comes from extrapolation of data that have shown improved OS with maintenance therapy after HCT. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Maintenance'</a>.)</p><p><a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> maintenance was incorporated into both arms of the randomized trials that demonstrated improved OS with VRd versus Rd (SWOG S0777) and with DRd versus Rd (MAIA) [<a href="#rid11">11,30,31</a>]. However, the impact of maintenance on the outcomes seen in these trials cannot be assessed given the lack of a maintenance-free control arm. </p><p>The trials that have evaluated maintenance therapy in patients not undergoing HCT have limitations. In some, factors other than maintenance differed between the two arms. In others, the regimens used are outdated. As an example, the FIRST trial demonstrated better OS with continuous Rd when compared with 18 months of <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, and <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a> (MPT) in transplant-ineligible patients with previously untreated MM [<a href="#rid32">32-34</a>]. However, the arms differed both in length of therapy and agents used. As another example, the FORTE trial demonstrated improved PFS with two-drug maintenance (<a class="drug drug_general" data-topicid="86042" href="/d/drug information/86042.html" rel="external">carfilzomib</a> plus <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>) when compared with lenalidomide maintenance (three year PFS from randomization to maintenance 75 versus 65 percent; HR 0.64; 95% CI 0.44-0.94) [<a href="#rid35">35</a>]. As maintenance was investigated as a second randomization, the population studied included patients with standard- and high-risk MM treated with different induction regimens with or without HCT. </p><p>A 2015 meta-analysis compared continuous therapy versus fixed-duration therapy in patients with newly diagnosed MM [<a href="#rid36">36</a>]. This analysis was restricted to the 1218 patients who were progression-free and alive at one year after random assignment (ie, those eligible for continuous therapy). Two trials used <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> maintenance while one used maintenance with <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> and <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a>. After a median follow-up of 52 months, maintenance therapy resulted in improved PFS (median 32 versus 16 months, HR 0.47; 95% CI 0.40-0.56), second PFS (median 55 versus 40 months, HR 0.61; 95% CI 0.50-0.75), and OS (69 versus 60 percent alive at four years, HR 0.69; 95% CI 0.54-0.88). The improved second PFS suggests that the administration of maintenance therapy did not adversely impact the ability to respond to subsequent therapy. However, it is not clear whether all patients in the control arms had access to lenalidomide and bortezomib at the time of relapse. Toxicity and impact on quality of life were not examined.</p><p>Studies have evaluated single-agent <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> as maintenance in standard-risk MM as there are known risks to continuous glucocorticoid therapy and the benefits are unclear. In two randomized trials, there was no clear benefit from the addition of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> to lenalidomide maintenance [<a href="#rid37">37,38</a>]. Another trial demonstrated similar efficacy and better tolerability with Rd for nine cycles followed by reduced-dose lenalidomide maintenance without <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> when compared with continuous Rd in intermediate-fit older adults [<a href="#rid39">39</a>]. (See <a class="local">'Lenalidomide plus dexamethasone'</a> below.)</p><p>An open-label, multicenter, randomized, phase III trial (Myeloma XI) compared maintenance with single-agent <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> (10 mg daily on 21 of 28 days per cycle) versus observation in 1917 patients with MM followed for a median of 31 months [<a href="#rid40">40</a>]. In a prespecified subgroup analysis of the 723 patients ineligible for transplant who underwent initial treatment with at least six cycles of induction that included <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, and either <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a> or lenalidomide, lenalidomide maintenance improved PFS (median 26 versus 11 months; HR 0.44, 95% CI 0.37-0.53) but not OS (OS at three years 67 versus 70 percent; HR 1.02, 95% CI 0.80-1.29). However, of the patients assigned to lenalidomide, approximately 70 percent had dose modifications and 15 percent discontinued lenalidomide due to toxicity.</p><p>There are limited data regarding <a class="drug drug_general" data-topicid="105607" href="/d/drug information/105607.html" rel="external">ixazomib</a> maintenance. In a placebo-controlled, randomized trial (TOURMALINE-MM4) of &gt;700 patients with newly diagnosed MM not undergoing autologous transplant, ixazomib maintenance prolonged PFS (median PFS 17 versus 9 months, HR 0.66, 95% CI 0.54-0.80) [<a href="#rid41">41</a>]. Rates of grade 3 or greater treatment-emergent adverse events were increased (37 versus 23 percent). The most common any grade adverse events were nausea (27 percent), vomiting (24 percent), and diarrhea (23 percent). </p><p class="headingAnchor" id="H513503163"><span class="h2">Prevention and management of complications</span><span class="headingEndMark"> — </span>In addition to therapy directed at the malignant clone, the management of most patients with MM includes preventative measures to reduce the incidence of skeletal events, kidney damage, infections, neuropathy, and thrombosis. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skeletal lesions and bone health</strong> – Osteoclast inhibitors (eg, bisphosphonate therapy or <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a>) are administered to prevent skeletal events in patients with one or more lesions on skeletal imaging and those with osteopenia  (<a class="graphic graphic_algorithm graphicRef127382" data-inline-graphics="127382" href="/d/graphic/127382.html" rel="external">algorithm 3</a>). (See  <a class="medical medical_review" href="/d/html/6663.html" rel="external">"Multiple myeloma: The use of osteoclast inhibitors"</a>.)</p><p></p><p class="bulletIndent1">Skeletal lesions can result in bone pain, pathologic fractures, and spinal cord compression.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pathologic fractures or impending fractures of long bones require stabilization. Vertebral fractures may benefit from kyphoplasty or vertebroplasty. Most pain related to lytic lesions can be controlled with the combination of analgesics and active myeloma chemotherapy. (See  <a class="medical medical_review" href="/d/html/132146.html" rel="external">"Management of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Spinal cord compression is a clinical emergency and should be suspected in patients with severe back pain, weakness, or paresthesias of the lower extremities, or bladder or bowel dysfunction or incontinence. (See  <a class="medical medical_review" href="/d/html/2820.html" rel="external">"Treatment and prognosis of neoplastic epidural spinal cord compression"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney impairment</strong> – All patients with MM should take measures to minimize kidney damage (eg, avoid nephrotoxins such as aminoglycosides and nonsteroidal anti-inflammatory drugs [NSAIDs] and maintain adequate hydration). Many medications used for myeloma require dose adjustment for kidney impairment (eg, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a>). Treatment of kidney impairment is directed at the underlying cause. (See  <a class="medical medical_review" href="/d/html/7211.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – Prophylactic measures used to minimize infection in patients with MM include yearly influenza vaccines; pneumococcal vaccine at the time of diagnosis; and prophylactic antibiotics during the first months of induction chemotherapy. Antiviral and pneumocystis prophylaxis may also be indicated. (See  <a class="medical medical_review" href="/d/html/13947.html" rel="external">"Infections in patients with multiple myeloma"</a>.)</p><p></p><p class="bulletIndent1">Patients suspected of having an infection should be treated promptly with empiric antibiotics. (See  <a class="medical medical_review" href="/d/html/13951.html" rel="external">"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thromboprophylaxis </strong>– Patients with MM are at increased risk of having comorbidities known to be risk factors for the development of venous thromboembolism (VTE) in the general population. In addition, treatment with immunomodulatory drugs (eg, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, <a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">pomalidomide</a>, <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a>) is associated with high rates of VTE. All patients with MM should have an assessment of their VTE risk so that appropriate prophylaxis may be employed  (<a class="graphic graphic_algorithm graphicRef122682" data-inline-graphics="122682" href="/d/graphic/122682.html" rel="external">algorithm 4</a>). (See  <a class="medical medical_review" href="/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuropathy</strong> – Peripheral neuropathy, often painful, can occur in association with various chemotherapeutic agents, including both proteasome inhibitors (especially <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>) and immunomodulatory agents. The frequency and severity of peripheral neuropathy with bortezomib can be reduced by adjusting the route (subcutaneous rather than intravenous administration) and frequency (once versus twice weekly) of administration. (See  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Specific recommendations for bortezomib'</a>.)</p><p></p><p class="bulletIndent1">Peripheral neuropathy is more frequent and severe in those who have previously received neurotoxic therapy and those with pre-existing neuropathy [<a href="#rid42">42</a>]. Regimens that do not include <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> (eg, <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">daratumumab</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>) may be preferred as initial therapy in such patients. (See <a class="local">'Daratumumab, lenalidomide, dexamethasone'</a> below.)</p><p></p><p class="bulletIndent1">When neuropathy occurs, it can impair quality of life and ability to perform activities of daily living. Management is discussed separately, including dose modification and/or treatment discontinuation. (See  <a class="medical medical_review" href="/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Bortezomib'</a> and  <a class="medical medical_review" href="/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Thalidomide and related agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypercalcemia</strong> – Patients with hypercalcemia may be asymptomatic or present with anorexia, nausea, vomiting, polyuria, polydipsia, constipation, weakness, confusion, or stupor. The treatment of hypercalcemia depends on the calcium level, the rapidity with which it developed, and the patient's symptoms. Emergency treatment with hydration, glucocorticoids, bisphosphonates, and/or hemodialysis/<a class="drug drug_general" data-topicid="9182" href="/d/drug information/9182.html" rel="external">calcitonin</a> is indicated for symptomatic patients. (See  <a class="medical medical_review" href="/d/html/850.html" rel="external">"Treatment of hypercalcemia"</a>.)</p><p></p><p class="headingAnchor" id="H5916919"><span class="h1">REVIEW OF CHEMOTHERAPY REGIMENS</span><span class="headingEndMark"> — </span>Several regimens are available for the treatment of newly diagnosed MM. The most common are discussed in the following sections. A choice among them is presented in more detail above  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>). (See <a class="local">'Choice of therapy'</a> above.)</p><p>Additional options for patients treated in resource-poor settings are presented separately. (See  <a class="medical medical_review" href="/d/html/6650.html" rel="external">"Multiple myeloma: Management in resource-limited settings"</a>.)</p><p class="headingAnchor" id="H3360227874"><span class="h2">Four-drug regimens</span><span class="headingEndMark"> — </span>Three-drug regimens are preferred over two-drug regimens whenever possible because they appear to provide an OS benefit. When compared with three-drug regimens, initial trial results also suggest that four-drug regimens deepen response and improve progression-free survival (PFS), albeit with an increase in toxicity and cost. As such, a choice between three- and four-drug regimens is largely driven by disease characteristics along with patient values and preferences. We prefer four-drug regimens for patients with high-risk MM and consider both three-drug and four-drug regimens to be acceptable options for patients with standard-risk MM. (See <a class="local">'Standard-risk myeloma'</a> above and <a class="local">'High-risk myeloma'</a> above.)</p><p class="headingAnchor" id="H1932623601"><span class="h3">Daratumumab, bortezomib, lenalidomide, dexamethasone</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">Daratumumab</a>, <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (DVRd) is one of our preferred options for the initial treatment of MM, although it does not have regulatory approval for this indication. Some experts are comfortable substituting <a class="drug drug_general" data-topicid="127258" href="/d/drug information/127258.html" rel="external">isatuximab</a> for daratumumab based on studies showing deep responses with this combination and the expectation that the two anti-CD38 monoclonal antibodies likely have similar efficacy, although they have not been directly compared [<a href="#rid43">43,44</a>]. (See <a class="local">'Standard-risk myeloma'</a> above and <a class="local">'High-risk myeloma'</a> above.)</p><p></p><p class="bulletIndent1">While the trials that have evaluated DVRd incorporated <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">daratumumab</a> into the induction, consolidation, and maintenance phases of treatment, data from the CASSIOPEIA trial suggest that those who receive a total of six cycles of daratumumab with induction do not appear to benefit from an additional two years of daratumumab maintenance [<a href="#rid45">45-47</a>]. Given the uncertainty of benefits, we do not routinely offer post-hematopoietic cell transplantation (HCT) maintenance daratumumab following six cycles of daratumumab-based quadruplet induction therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy and toxicity</strong> – DVRd has been compared with <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (VRd) in two randomized trials. The addition of <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">daratumumab</a> to VRd deepens responses and improves PFS, albeit with a modest increased toxicity and cost. The impact on overall survival (OS) is unclear as follow-up is short. </p><p></p><p class="bulletIndent1">In a phase 2 trial (GRIFFIN), 207 patients with newly diagnosed MM eligible for HCT were randomly assigned to receive induction with four cycles of VRd with or without <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">daratumumab</a> (DVRd versus VRd), followed by autologous HCT plus two cycles of consolidation with the assigned regimen, then up to two years of maintenance with either <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> alone or with lenalidomide plus daratumumab [<a href="#rid8">8,9</a>]. After a median follow-up of 50 months, DVRd improved stringent complete response rates (67 versus 48 percent) and PFS (four-year PFS 87 versus 70 percent; hazard ratio [HR] 0.45, 95% CI 0.21-0.95). Median OS was not reached for either group (HR 0.90, 95% CI 0.31-2.56). Toxicity was greater with DVRd, with higher rates of neutropenia and upper respiratory tract infections. </p><p></p><p class="bulletIndent1">A subsequent phase 3 trial (PERSEUS) compared DVRd versus VRd in 709 patients with newly diagnosed MM eligible for HCT [<a href="#rid10">10</a>]. The trial design was similar to GRIFFIN except that maintenance was continued until progression for most patients. Those treated with DVRd who had sustained measurable residual disease (MRD) negativity were eligible to discontinue <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">daratumumab</a> and continue <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> maintenance until progression. After a median follow-up of 48 months, DVRd improved MRD negativity rates (75 versus 48 percent) and PFS (48-month PFS 84 versus 68 percent; HR 0.42, 95% CI 0.30-0.59). OS data are immature with a small percentage of deaths in both arms (9.6 versus 12.4 percent). The addition of daratumumab increased the rates of neutropenia, thrombocytopenia, and infections. Stem cell mobilization and collection were feasible with DVRd, although a higher percentage of patients received <a class="drug drug_general" data-topicid="9517" href="/d/drug information/9517.html" rel="external">plerixafor</a> for mobilization (40 versus 23 percent). </p><p></p><p class="headingAnchor" id="H3580234177"><span class="h3">Isatuximab-based four-drug regimens</span><span class="headingEndMark"> — </span>Data are limited regarding the use of isatuximab-based four-drug regimens. Initial reports from two randomized trials have reported deeper responses with the addition of <a class="drug drug_general" data-topicid="127258" href="/d/drug information/127258.html" rel="external">isatuximab</a> to <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (IsaVRd) [<a href="#rid44">44</a>] and to <a class="drug drug_general" data-topicid="86042" href="/d/drug information/86042.html" rel="external">carfilzomib</a>, lenalidomide, and dexamethasone (IsaKRd) [<a href="#rid48">48</a>]. Some experts are comfortable using IsaVRd instead of DVRd based on the expectation that the two anti-CD38 monoclonal antibodies likely have similar efficacy, although they have not been directly compared. In contrast, further follow-up is needed regarding the use of IsaKRd given the toxicity of the carfilzomib, lenalidomide, and dexamethasone (KRd) backbone, as discussed separately. (See <a class="local">'Carfilzomib, lenalidomide, dexamethasone'</a> below.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>IsaVRd</strong> – IsaVRd has not been directly compared with other four-drug regimens, and follow-up comparing it to VRd is short. </p><p></p><p class="bulletIndent1">The addition of <a class="drug drug_general" data-topicid="127258" href="/d/drug information/127258.html" rel="external">isatuximab</a> to VRd deepens responses without a modest increase in toxicity. The impact on PFS and OS is unclear as follow-up is short. </p><p></p><p class="bulletIndent1">In a phase 3 trial (GMMG-HD7), 660 patients with newly diagnosed MM eligible for HCT were randomly assigned to receive induction with three cycles of VRd with or without <a class="drug drug_general" data-topicid="127258" href="/d/drug information/127258.html" rel="external">isatuximab</a> (IsaVRd versus VRd) [<a href="#rid44">44</a>]. An initial analysis reported that IsaVRd resulted in deeper responses with improved MRD negativity rates after induction (50 versus 36 percent; overall response [OR] 1.82, 95% CI 1.33-2.48). IsaVRd resulted in higher rates of grade 3 or 4 neutropenia (23 versus 7 percent) and grade 3 or 4 infections (12 versus 10 percent). Treatment-related deaths included one in the IsaVRd arm (septic shock) and four in the VRd arm. The protocol included autologous HCT and a second randomization that investigates the addition of isatuximab to maintenance <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>. Data regarding longer-term outcomes are pending. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IsaKRd</strong> – IsaKRd is an experimental regimen in patients with newly diagnosed MM, and we do not use it, regardless of risk stratification  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>). While initial studies suggest that IsaKRd has activity in this setting [<a href="#rid48">48-50</a>], it has not been directly compared with other four-drug regimens, and follow-up comparing it to KRd is short. In addition, extrapolation of other data suggests that the backbone of KRd is not more effective than VRd and has increased toxicity and costs. </p><p></p><p class="bulletIndent1">The addition of <a class="drug drug_general" data-topicid="127258" href="/d/drug information/127258.html" rel="external">isatuximab</a> to KRd deepens responses, albeit with a moderate increase in toxicity. The impact on PFS and OS is unclear as follow-up is short. </p><p></p><p class="bulletIndent1">In a phase 3 trial (IsKia EMN24) presented in abstract form, 302 patients with newly diagnosed MM eligible for HCT were randomly assigned to receive induction with four cycles of KRd with or without <a class="drug drug_general" data-topicid="127258" href="/d/drug information/127258.html" rel="external">isatuximab</a> (IsaKRd versus KRd), followed by autologous HCT plus four cycles of consolidation with the assigned regimen at full dose, then 12 cycles of consolidation with reduced doses of the assigned regimen [<a href="#rid48">48</a>]. After a median follow-up of 21 months, IsaKRd improved MRD negativity rates (67 versus 48 percent with a threshold of 10<sup>-6</sup> measured by next generation sequencing). There was a moderate increase in toxicity with IsaKRd, demonstrating a higher percentage of grade ≥3 neutropenia (36 versus 22 percent), although a difference in grade ≥3 infection rates did not reach statistical significance (15 versus 11 percent). PFS and OS data are immature. There were four deaths in the IsaKRd arm (one progressive disease, three infections) and one death in the KRd arm (infection).</p><p></p><p class="headingAnchor" id="H1623108388"><span class="h3">Daratumumab, bortezomib, thalidomide, dexamethasone</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">Daratumumab</a>, <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (DVTd) is approved by the US Food and Drug Administration (FDA) for the treatment of patients with newly diagnosed MM who are eligible for autologous HCT. However, this and other thalidomide-containing regimens are not commonly used in the United States as initial therapy. DVTd is used more frequently in other countries.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy and toxicity</strong> – When compared with VTd, DVTd improves PFS without a major increase in toxicity. OS data are immature.</p><p></p><p class="bulletIndent1">In a phase 3 trial (CASSIOPEIA), 1085 patients with newly diagnosed MM eligible for HCT were randomly assigned to receive induction with four cycles of <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> with or without <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">daratumumab</a> (DVTd versus VTd), followed by autologous HCT plus two cycles of consolidation with the assigned regimen [<a href="#rid45">45-47</a>]. Those achieving a partial response or better were then randomly assigned to observation versus daratumumab maintenance for a maximum of two years. After a median follow-up of 45 months, the addition of daratumumab to induction resulted in: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved PFS (HR 0.58, 95% CI 0.47-0.72). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>While the survival data are immature, there were fewer deaths in the DVTd arm (41 versus 73; HR 0.54, 95% CI 0.37-0.79), a finding that would be clinically significant if confirmed on further follow-up.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>While collection of CD34+ cells was more difficult in the DVTd arm, approximately 90 percent of patients in both arms proceeded with HCT and achieved hematopoietic reconstitution.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When compared with VTd, DVTd increased neutropenia, lymphopenia, and pneumonia. Infusion reactions to <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">daratumumab</a> (mostly mild) were reported in 35 percent.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">Daratumumab</a> maintenance improved PFS among patients who underwent VTd induction (HR 0.32, 95% CI 0.23-0.46) but not among those who underwent DVTd induction (HR 1.02, 95% CI 0.71-1.47). Infusion-related reactions were reported in 55 percent of patients receiving daratumumab maintenance (mostly grade 1 or 2) and 3 percent discontinued daratumumab due to an adverse event.</p><p></p><p class="bulletIndent1">The results of the second randomization question the value of continued <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">daratumumab</a> maintenance after induction with a daratumumab-containing regimen. Those who received a total of six cycles of daratumumab with induction did not appear to benefit from an additional two years of daratumumab maintenance. Given the uncertainty of benefit, we do not routinely offer maintenance daratumumab following six cycles of daratumumab-based quadruplet induction therapy and HCT.</p><p></p><p class="headingAnchor" id="H3123486652"><span class="h3">Daratumumab, bortezomib, melphalan, prednisone</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">Daratumumab</a>, <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a>, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (DVMP) is approved by the US FDA for the treatment of patients with newly diagnosed MM who are ineligible for autologous HCT. However, this and other melphalan-containing regimens are not commonly used in the United States as initial therapy. DVMP is used more frequently in other countries.</p><p></p><p class="bulletIndent1">Importantly, DVMP is not an appropriate regimen for patients who are candidates for HCT. Melphalan-containing regimens should <strong>be avoided</strong> prior to the collection of stem cells, since their use has been associated with damage to the hematopoietic stem cell compartment. Melphalan-containing regimens have a larger role in the management of myeloma in resource-poor settings. (See  <a class="medical medical_review" href="/d/html/6650.html" rel="external">"Multiple myeloma: Management in resource-limited settings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy and toxicity</strong> – When compared with VMP, DVMP improves both PFS and OS without a major increase in toxicity. </p><p></p><p class="bulletIndent1">In a phase 3 trial (ALCYONE), 706 patients with newly diagnosed MM <strong>ineligible</strong> for HCT were randomly assigned to receive nine cycles of <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a>, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> with or without <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">daratumumab</a> until disease progression (DVMP versus VMP) [<a href="#rid51">51,52</a>]. The addition of daratumumab resulted in: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Higher rates of OR (91 versus 74 percent) and minimal residual disease negativity (22 versus 6 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Superior PFS (51 versus 19 percent at three years, median 36 versus 19 months; HR 0.42, 95% CI 0.34-0.51).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Superior OS (78 versus 68 percent at three years; HR 0.60, 95% CI 0.46-0.80).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>More grade 3 or 4 infections (22 versus 15 percent during induction and 11 percent during maintenance). Daratumumab-related infusion reactions occurred in 28 percent.</p><p></p><p class="bulletIndent1">While these results suggest that the addition of <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">daratumumab</a> during induction and maintenance can deepen responses and delay progression, it is not known whether PFS was improved due to the addition of daratumumab, the use of maintenance, or both. An OS benefit was seen, but only 10 percent of patients in the control arm received daratumumab at the time of progression, and all of these patients were alive at three years. As such, it is not known whether this OS benefit is due to the incorporation of daratumumab into initial therapy, or the use of suboptimal second and subsequent therapies in the majority of patients.</p><p></p><p class="headingAnchor" id="H418682808"><span class="h2">Three-drug regimens</span><span class="headingEndMark"> — </span>Three-drug regimens discussed below are a mainstay of initial therapy for most patients with MM based on numerous phase 3 trials summarized below. A choice among these regimens is presented in more detail separately  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>). (See <a class="local">'Choice of therapy'</a> above.)</p><p class="headingAnchor" id="H2068291704"><span class="h3">Bortezomib, lenalidomide, dexamethasone</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – The combination of <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (VRd)  (<a class="graphic graphic_table graphicRef91054" data-inline-graphics="91054" href="/d/graphic/91054.html" rel="external">table 3</a>) is one of our preferred treatment options for MM  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>). Specific administration considerations are discussed separately. (See  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – When compared with <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> plus <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (Rd) alone, VRd improves OS. </p><p></p><p class="bulletIndent1">In a multicenter, open-label phase 3 trial (SWOG S0777), 525 patients with previously untreated MM were randomly assigned to receive six months of induction therapy with either VRd or Rd, each followed by Rd maintenance until progression or unacceptable toxicity [<a href="#rid11">11,53</a>]. Approximately one-third of patients had high-risk disease. At a median follow-up of 84 months, VRd resulted in the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Higher rates of OR (82 versus 72 percent) and complete response (CR; 16 versus 8 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Superior PFS (median 41 versus 29 months; HR 0.74, 95% CI 0.59-0.93)</p><p class="bulletIndent2"><span class="glyph">•</span>Superior OS (median not reached versus 69 months; HR 0.71, 95% CI 0.54-0.93)</p><p></p><p class="bulletIndent1">In a subset analysis, the benefit with VRd was also seen in patients with high-risk disease with median PFS numerically higher with VRd (38 versus 16 months), although these differences were not statistically significant likely due to small numbers. (See  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Specific recommendations for bortezomib'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – In SWOG S0777, VRd was associated with greater toxicity and a greater number of patients discontinuing therapy due to toxicity (55 versus 22 patients) [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1">Major toxicities of VRd include peripheral neuropathy, transient cytopenias, fatigue, and gastrointestinal distress. Thromboprophylaxis and antiviral prophylaxis are required. Of note, the SWOG S0777 trial VRd protocol used twice-weekly intravenous <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>. Neurotoxicity rates are lower with once-weekly subcutaneous bortezomib.</p><p></p><p class="bulletIndent1">Toxicities, dose adjustments for organ impairment, and options for thromboembolism prophylaxis are discussed separately. (See  <a class="medical medical_review" href="/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism"</a> and  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="headingAnchor" id="H3403164524"><span class="h3">Daratumumab, lenalidomide, dexamethasone</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – The combination of <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">daratumumab</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (DRd)  (<a class="graphic graphic_table graphicRef119710" data-inline-graphics="119710" href="/d/graphic/119710.html" rel="external">table 5</a>) has demonstrated tolerability and efficacy in the management of patients with newly diagnosed MM. It is an option for the initial treatment of MM, especially for patients who cannot receive or tolerate <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> (eg, those with pre-existing neuropathy). DRd is approved by the US FDA for the treatment of patients with newly diagnosed MM who are ineligible for autologous HCT. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – When compared with <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> plus <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (Rd) alone, DRd improves OS without a major increase in toxicity. </p><p></p><p class="bulletIndent1">In a multicenter, open-label phase 3 trial (MAIA), 737 patients with newly diagnosed MM ineligible for HCT were randomly assigned to receive Rd with or without <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">daratumumab</a> (Rd versus DRd) [<a href="#rid30">30</a>]. Treatment was continued until disease progression or unacceptable side effects. After a median follow-up of 56 months, the addition of daratumumab resulted in [<a href="#rid12">12</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Deeper responses (CR or better 51 versus 30 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved PFS (five-year PFS 53 versus 29 percent; median not reached versus 34 months; HR 0.53, 95% CI 0.43-0.66). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved OS (five-year OS 66 versus 53 percent; HR 0.68, 95% CI 0.53-0.86).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved measures of healthcare-related quality of life, including quicker, sustained improvements in patient-reported outcomes, including pain [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1">Use of DRd in the relapsed setting is discussed separately. (See  <a class="medical medical_review" href="/d/html/121127.html" rel="external">"Multiple myeloma: Treatment of first or second relapse", section on 'Daratumumab, lenalidomide, dexamethasone (DRd)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – In MAIA, DRd increased rates of grade 3 or 4 neutropenia (54 versus 37 percent) and pneumonia (19 versus 11 percent) [<a href="#rid30">30</a>]. More patients receiving <a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">daratumumab</a> had dose adjustments or discontinuation of <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> (74 versus 56 percent). Infusion reactions were reported in 41 percent of patients receiving daratumumab. Most reactions were mild and associated with the first infusion.</p><p></p><p class="bulletIndent1">Major toxicities of DRd include cytopenias, infections, and gastrointestinal distress. Thromboprophylaxis and antiviral prophylaxis are required.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">Daratumumab</a> was administered intravenously (IV) in the MAIA trial, but the subcutaneous formulation is now more widely used as it is equally effective as IV, the rate of infusion reactions is lower, and the formulation is more convenient for patients given the brief period of administration. </p><p></p><p class="bulletIndent1">Toxicities, dose adjustments for organ impairment, and options for thromboembolism prophylaxis are discussed separately. (See  <a class="medical medical_review" href="/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism"</a> and  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="headingAnchor" id="H2050255773"><span class="h3">Bortezomib, cyclophosphamide, dexamethasone</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – The combination of <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (VCd, also called CyBorD)  (<a class="graphic graphic_table graphicRef50061" href="/d/graphic/50061.html" rel="external">table 6</a>) has demonstrated tolerability and efficacy in the management of patients with newly diagnosed MM. In general, we prefer VRd or DRd given the OS benefit for these regimens when compared with Rd  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>). VCd is a reasonable alternative for patients at higher risk of complications with <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> (eg, acute kidney failure, increased thromboembolic risk) and for those in countries in which lenalidomide is not approved for initial therapy. (See <a class="local">'Acute kidney failure'</a> above.)</p><p></p><p class="bulletIndent1">The dosing schedule for VCd typically used in practice, with weekly rather than twice-weekly dosing of <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, is a modification of that used in clinical trials in order to reduce neurotoxicity and dexamethasone-related toxicity. (See  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy and toxicity</strong> – In a phase 2 trial (EVOLUTION), 140 patients with newly diagnosed MM were randomly assigned to receive initial treatment with <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> in combination with <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> (VRd), <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (VCd), or both (VDCR) [<a href="#rid13">13</a>]. After an interim analysis, the protocol was amended to change the VCd regimen to include an additional dose of cyclophosphamide (VCd-mod). Following four cycles of therapy, OR rates were 73, 63, 82, and 80 percent in patients who received VRd, VCd, VCd-mod, and VDCR, respectively. Corresponding rates of very good partial response (VGPR) or better were 32, 13, 41, and 33 percent. Approximately 88 percent of patients receiving VCd-mod experienced at least one severe (grade 3/4) toxicity with the most common being neutropenia (24 percent), neuropathy (18 percent), and anemia (12 percent).</p><p></p><p class="bulletIndent1">Further details on toxicities and dose adjustments for organ impairment are discussed separately. (See  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="headingAnchor" id="H3283289376"><span class="h3">Bortezomib, thalidomide, dexamethasone</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – The combination of <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (VTd)  (<a class="graphic graphic_table graphicRef101205" href="/d/graphic/101205.html" rel="external">table 7</a>) is a reasonable alternative if it is not possible to administer VRd or DRd because of lack of availability of <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> as induction therapy, and in patients presenting with acute kidney failure. In these circumstances, VTd and VCd are two primary options, and the choice between the two is based on experience with the regimen and drug availability; in the United States, VCd is more widely used than VTd.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy and toxicity</strong> – Randomized trials have compared VTd  (<a class="graphic graphic_table graphicRef101205" href="/d/graphic/101205.html" rel="external">table 7</a>) versus VCd, <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a> and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (Td), and <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> plus dexamethasone (VD). When compared with VCd, VTd results in higher response rates, although PFS and OS data are not mature. The addition of bortezomib to Td improves response rates and PFS; longer follow-up is required to evaluate OS. In contrast, the addition of thalidomide to VD has yet to demonstrate an improvement in PFS or OS.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>VTD versus VCD – In a multicenter phase 3 trial (IFM2013-04), 340 patients with newly diagnosed MM were randomly assigned to receive initial treatment with four cycles of VTD or VCD, each followed by HCT [<a href="#rid54">54</a>]. VTD resulted in a higher OR rate (92 versus 83 percent) and VGPR rate (66 versus 56 percent). VTD resulted in more neurologic toxicity and less hematologic toxicity. There were five deaths during induction, two in the VTD arm (infection, pulmonary embolism) and three in the VCD arm (infections and disease progression). Survival data are not mature.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>VTD versus TD – Two randomized trials comparing VTD versus TD included a total of 860 patients with previously untreated MM undergoing single or double autologous HCT [<a href="#rid55">55-57</a>]. The addition of <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> did not impact stem cell mobilization and resulted in higher response rates and improved PFS. Patients receiving VTD had higher rates of peripheral neuropathy, thromboembolism, infection, and skin rash, but lower rates of gastrointestinal distress.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>VTD versus VD<strong> </strong>– Two randomized trials have compared VTD versus VD. One trial in HCT-eligible patients compared lower than usual doses of <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> and <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a> (vtD) versus standard doses of VD and demonstrated deeper responses and less peripheral neuropathy in those assigned to vtD [<a href="#rid58">58</a>]. vtD therapy was associated with a significantly higher percentage of patients requiring the addition of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> in order to collect an adequate number of stem cells. In another trial, 502 patients with previously untreated myeloma who were not candidates for HCT were randomly assigned to receive VTD, VD, or bortezomib, <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a>, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (VMP) [<a href="#rid59">59</a>]. At a median follow-up of 43 months, there was no significant difference in median PFS (15, 15, and 17 months) or OS (52, 50, and 53 months).</p><p></p><p class="bulletIndent1">Further details on toxicities, dose adjustments for organ impairment, and options for thromboembolism prophylaxis are discussed separately. (See  <a class="medical medical_review" href="/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism"</a> and  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="headingAnchor" id="H1947578033"><span class="h3">Nonstandard regimens</span><span class="headingEndMark"> — </span>The regimens described below have not been approved by regulatory agencies for the initial treatment of MM and there have been concerns raised about use in this population. They are approved for use in the relapsed setting, and there may be specific scenarios where their use for initial treatment may be reasonable.</p><p class="headingAnchor" id="H3927596065"><span class="h4">Ixazomib, lenalidomide, dexamethasone</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – <a class="drug drug_general" data-topicid="105607" href="/d/drug information/105607.html" rel="external">Ixazomib</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (IRd) is an all oral three-drug regimen that is a treatment option for relapsed MM  (<a class="graphic graphic_table graphicRef106536" href="/d/graphic/106536.html" rel="external">table 8</a>). Use in previously untreated patients is not approved by regulatory agencies and thus should be limited at this time [<a href="#rid60">60</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – A placebo controlled, randomized trial (TOURMALINE-MM2) evaluated the addition of <a class="drug drug_general" data-topicid="105607" href="/d/drug information/105607.html" rel="external">ixazomib</a> to <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> in 705 transplant-ineligible patients with newly diagnosed MM [<a href="#rid61">61</a>]. Patients received 18 cycles of IRd or placebo-RD, followed by a lower dose of lenalidomide with lower-dose ixazomib or placebo until progression or toxicity. </p><p></p><p class="bulletIndent1">IRd resulted in a numerically higher median PFS, which did not reach statistical significance but would be clinically meaningful if true (median PFS 35 versus 22 months, HR 0.83, 95% CI 0.68-1.02). This benefit was seen in all prespecified subgroups, including the 280 patients with high-risk cytogenetics (median PFS 24 versus 18 months, HR 0.69, 95% CI 0.51-0.94). An OS difference has not been demonstrated (HR 0.998, 95% CI 0.79-1.26). </p><p></p><p class="bulletIndent1">Although IRd was not directly compared with VRd or DRd in this trial and cross-trial comparisons have limitations, the PFS benefit seen with IRd appears to be less substantial than that seen with VRd in the SWOG S0777 trial and with DRd in the MAIA trial [<a href="#rid11">11,30</a>]. (See <a class="local">'Bortezomib, lenalidomide, dexamethasone'</a> above and <a class="local">'Daratumumab, lenalidomide, dexamethasone'</a> above.)</p><p></p><p class="bulletIndent1">Use of IRd in relapsed/refractory MM is discussed separately. (See  <a class="medical medical_review" href="/d/html/121127.html" rel="external">"Multiple myeloma: Treatment of first or second relapse", section on 'Ixazomib, lenalidomide, dexamethasone (IRd)'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – Among patients treated with IRd on TOURMALINE-MM2, there was a small increase in grade 3 or 4 treatment-emergent adverse events (88 versus 81 percent), with lower rates of neutropenia and increased rates of diarrhea, rash, thrombocytopenia, arrhythmia, pneumonia, and heart failure. </p><p></p><p class="bulletIndent1">Further details on toxicities, dose adjustments for organ impairment, and options for thromboembolism prophylaxis are discussed separately. (See  <a class="medical medical_review" href="/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism"</a> and  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="headingAnchor" id="H3950408767"><span class="h4">Carfilzomib, lenalidomide, dexamethasone</span><span class="headingEndMark"> — </span>We generally do not use <a class="drug drug_general" data-topicid="86042" href="/d/drug information/86042.html" rel="external">carfilzomib</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (KRd) in patients with newly diagnosed MM, regardless of risk stratification  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>). </p><p>While prospective studies have shown deep responses following KRd plus autologous HCT in newly diagnosed MM [<a href="#rid35">35,62,63</a>], randomized trials have not compared this approach to VRd plus HCT, and extrapolation from studies in the non-transplant setting suggests similar efficacy, but greater toxicity. </p><p>In a multicenter phase 3 trial (ENDURANCE E1A11), over 1000 patients with previously untreated MM with no intent for early HCT were randomly assigned to nine months of induction with either KRd or VRd, each followed by a second randomization to <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> maintenance given for either two years or until disease progression or unacceptable toxicity [<a href="#rid64">64</a>]. The vast majority of patients had standard-risk MM; the trial excluded patients with del17p, t(14;16), t(14;20), plasma cell leukemia, or lactate dehydrogenase (LDH) &gt;2 times upper limit of normal. VRd and KRd resulted in similar PFS (median PFS 34 versus 35 months, HR 1.04, 95% CI 0.83-1.31) and OS (3-year OS 84 versus 86 percent, HR 0.98, 95% CI 0.71-1.36). VRd was associated with more peripheral neuropathy, while KRd was associated with more dyspnea, hypertension, heart failure, and acute kidney injury. </p><p class="headingAnchor" id="H861939694"><span class="h2">Two-drug regimens</span><span class="headingEndMark"> — </span>Three-drug regimens are preferred over two-drug regimens whenever possible because they appear to provide an OS benefit. The two-drug regimens discussed below are not used frequently, but they are of importance in frail patients who may not be able to tolerate standard three-drug regimens.</p><p class="headingAnchor" id="H666989563"><span class="h3">Lenalidomide plus dexamethasone</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> plus low-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (Rd)  (<a class="graphic graphic_table graphicRef56451" href="/d/graphic/56451.html" rel="external">table 4</a>) is an effective oral regimen for the initial treatment of MM and is our preferred regimen for frail patients with standard-risk MM unable to tolerate a three-drug regimen  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>). While the FIRST trial continued Rd until progression, a subsequent trial supports switching to a reduced-dose lenalidomide maintenance without dexamethasone after completing 8 to 12 cycles of Rd. (See <a class="local">'Frail adults'</a> above and <a class="local">'Risk-stratified treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Prospective trials have demonstrated the efficacy of Rd in the initial treatment of MM when compared with <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> alone and with the combination of <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a>, plus <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> and <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a> (MPT) [<a href="#rid32">32-34,65-67</a>]. </p><p></p><p class="bulletIndent1">In the FIRST trial, 1623 patients with previously untreated MM who were not candidates for HCT (median age 73 years) were randomly assigned to one of three initial treatment options: Rd until progression; Rd for 18 months; or MPT for 18 months [<a href="#rid32">32-34</a>]. At a median follow-up of 67 months, continuous Rd resulted in the following, when compared with MPT:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Higher rates of VGPR or better (48 versus 30 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Shorter time to response (2 versus 3 months)</p><p class="bulletIndent2"><span class="glyph">•</span>Longer PFS (median 26 versus 22 months; HR 0.69)</p><p class="bulletIndent2"><span class="glyph">•</span>Superior OS (median 59 versus 49 months; HR 0.78)</p><p class="bulletIndent2"><span class="glyph">•</span>Lower rates of neutropenia, thrombocytopenia, neuropathy, and constipation</p><p class="bulletIndent2"><span class="glyph">•</span>Higher rates of infections, venous thromboembolism, and cataracts</p><p class="bulletIndent2"><span class="glyph">•</span>No increase in second primary malignancies (7 versus 9 percent)</p><p></p><p class="bulletIndent1">In the same trial, Rd administered until progression resulted in longer PFS and time until second anti-myeloma therapy than when Rd was stopped after 18 months (median PFS 70 versus 40 months). There was no significant difference seen in the rate of VGPR or better or in OS. Cumulative toxicity rates were higher in patients taking Rd until progression. Given the PFS improvement and general tolerability, we prefer to continue treatment until progression unless there is toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduced-dose </strong><strong>lenalidomide</strong><strong> for maintenance</strong> – Transition to a reduced-dose <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> maintenance without <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> is supported by a phase 3 trial of 199 intermediate-fit older adults with newly diagnosed MM randomly assigned to continuous Rd until progression or to nine cycles of Rd followed by maintenance with a lower dose of lenalidomide (10 mg daily for 21 out of 28 days each cycle) without dexamethasone (Rd-R) [<a href="#rid39">39</a>]. After a median follow-up of 37 months, Rd-R resulted in trends toward improved PFS (median 20 versus 18 months, HR 0.78; 95% CI 0.55-1.10) and OS (three-year OS 74 versus 63 percent; HR 0.62, 95% CI 0.37-1.03), although these have not reached statistical significance and OS data are immature. Rd-R was better tolerated with less grade 3 or greater non-hematologic toxicity (33 versus 43 percent) and fewer lenalidomide dose reductions (45 versus 62 percent). </p><p></p><p class="bulletIndent1">As a result, for frail older adult patients treated with Rd as initial therapy, we suggest discontinuing <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> after 8 to 12 cycles of Rd, and continuing <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> alone as maintenance. This trial has similar implications for other MM regimens used in newly diagnosed disease in the nontransplant setting that incorporate maintenance dexamethasone (eg, VRd). If there is good disease control after at least one year of initial therapy on such regimens, it is reasonable to omit dexamethasone and continue with lenalidomide maintenance alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – Further details on toxicities, dose adjustments for organ impairment, and options for thromboembolism prophylaxis are discussed separately. (See  <a class="medical medical_review" href="/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism"</a> and  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="headingAnchor" id="H3785521960"><span class="h3">Bortezomib plus dexamethasone</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – The combination of <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> plus <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (Vd) is a two-drug regimen that may be offered to older and/or frail adults with significant kidney impairment. Vd requires a twice-weekly bortezomib schedule, which is associated with a higher risk of severe peripheral neuropathy than that seen with three-drug regimens that use once-weekly dosing. When possible, we prefer the three-drug regimen bortezomib, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, and dexamethasone (VRd)  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>). (See <a class="local">'Bortezomib, lenalidomide, dexamethasone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy and toxicity</strong> – A phase 2 trial examined the use of six cycles of Vd followed by autologous HCT in the treatment of 40 newly diagnosed, previously untreated patients with MM [<a href="#rid68">68</a>]. The OR rate before HCT was 65 percent with the majority of responses occurring within the first two cycles of treatment. The OR rate after HCT was 88 percent with 33 percent CR and 22 percent VGPR. Toxicity was mild.</p><p></p><p class="bulletIndent1">A phase 3 trial randomly assigned therapy with Vd or VAD (<a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>) as induction therapy prior to autologous HCT in 482 patients with newly diagnosed MM [<a href="#rid69">69</a>]. Vd resulted in significantly higher response rates and a trend toward longer PFS. No improvement in OS was seen. This study shows that superior VGPR and CR rates may not translate into meaningful improvements in PFS or OS, and it illustrates the limitations of CR and VGPR as surrogate endpoints in myeloma.</p><p></p><p class="bulletIndent1">Further details on toxicities and dose adjustments for organ impairment are discussed separately. (See  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Proteasome inhibitors'</a>.)</p><p></p><p class="headingAnchor" id="H851996749"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114824.html" rel="external">"Society guideline links: Multiple myeloma"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/688.html" rel="external">"Patient education: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/690.html" rel="external">"Patient education: Multiple myeloma treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/686.html" rel="external">"Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk stratification</strong> – While experts differ in their preferred initial treatment regimen for multiple myeloma (MM), there is general agreement that the choice must incorporate genetic features, risk of neuropathy and thrombosis, kidney function, and treatment burdens. (See <a class="local">'Risk stratification and other factors impacting choice'</a> above.)</p><p></p><p class="bulletIndent1">MM can be categorized as standard-risk or high-risk disease based on the results of fluorescence in situ hybridization (FISH) for specific translocations and/or deletions and certain other tests  (<a class="graphic graphic_table graphicRef78344" href="/d/graphic/78344.html" rel="external">table 2</a>). This risk stratification has considerable prognostic value and also helps guide treatment  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction for</strong> <strong>standard</strong>-<strong>risk MM</strong> – For most patients with standard-risk MM, we suggest induction with either a four-drug regimen or a three-drug regimen rather than a two-drug regimen (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Most trials suggest that the addition of a third drug improves overall survival while the addition of a fourth drug deepens responses and improves progression-free survival (PFS), albeit with an increase in toxicity and cost. (See <a class="local">'Standard-risk myeloma'</a> above.)</p><p></p><p class="bulletIndent1">Choice of therapy is largely driven by disease characteristics and comorbidities, along with patient values, preferences, and access. Acceptable regimens include: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">Daratumumab</a>, <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (DVRd) is a reasonable option for patients who prioritize PFS. (See <a class="local">'Daratumumab, bortezomib, lenalidomide, dexamethasone'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">Bortezomib</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (VRd) is an effective option for those who prioritize avoiding the costs and toxicity of adding a fourth drug  (<a class="graphic graphic_table graphicRef91054" href="/d/graphic/91054.html" rel="external">table 3</a>). (See <a class="local">'Bortezomib, lenalidomide, dexamethasone'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">Daratumumab</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (DRd)  (<a class="graphic graphic_table graphicRef119710" href="/d/graphic/119710.html" rel="external">table 5</a>) is an alternative, especially for patients who may not tolerate <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> (eg, those with pre-existing neuropathy). (See <a class="local">'Daratumumab, lenalidomide, dexamethasone'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The doses and schedules of VRd and DRd can be modified for use in frail adults. <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> plus <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (Rd)  (<a class="graphic graphic_table graphicRef56451" href="/d/graphic/56451.html" rel="external">table 4</a>) is an acceptable alternative for frail adults who cannot tolerate a three-drug regimen. (See <a class="local">'Frail adults'</a> above and <a class="local">'Lenalidomide plus dexamethasone'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">Bortezomib</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (VCd)  (<a class="graphic graphic_table graphicRef50061" href="/d/graphic/50061.html" rel="external">table 6</a>) is an alternative for patients at higher risk of complications with <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> (eg, acute kidney failure, increased thromboembolic risk). (See <a class="local">'Bortezomib, cyclophosphamide, dexamethasone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-induction management for standard-risk MM</strong> – Patients who are eligible for autologous hematopoietic cell transplantation (HCT) receive three to six cycles of induction therapy followed by stem cell collection  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>). Then a decision is made regarding whether to proceed with HCT (early HCT strategy) or continue the same chemotherapy regimen, reserving HCT for first relapse (delayed HCT strategy). (See <a class="local">'Incorporating HCT in eligible patients'</a> above.)</p><p></p><p class="bulletIndent1">Those not proceeding to early HCT are typically treated with 8 to 12 cycles, as tolerated, followed by maintenance with single-agent <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> until progression. (See <a class="local">'Maintenance for patients who are ineligible for or defer HCT'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-risk MM</strong> – Patients with high-risk MM are encouraged to participate in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=6647" target="_blank">clinical trials</a> of novel strategies, since they tend to do less well with conventional treatment. Outside of a trial, we use a proteasome inhibitor-containing or daratumumab-containing regimen  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 2</a>). (See <a class="local">'High-risk myeloma'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Not HCT eligible</strong> – For patients who are not candidates for autologous HCT, we suggest VRd  (<a class="graphic graphic_table graphicRef91054" href="/d/graphic/91054.html" rel="external">table 3</a>) or DRd  (<a class="graphic graphic_table graphicRef119710" href="/d/graphic/119710.html" rel="external">table 5</a>) rather than Rd (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). VCd  (<a class="graphic graphic_table graphicRef50061" href="/d/graphic/50061.html" rel="external">table 6</a>) is an alternative for patients at higher risk of complications with <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> (eg, acute kidney failure, increased thromboembolic risk). After 8 to 12 cycles, we offer maintenance that includes both lenalidomide and <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> until time of disease progression. </p><p></p><p class="bulletIndent2">We do not use <a class="drug drug_general" data-topicid="86042" href="/d/drug information/86042.html" rel="external">carfilzomib</a>, as the substitution of carfilzomib for <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> does not improve efficacy and worsens toxicity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>HCT eligible</strong> – For patients who are candidates for HCT, we suggest induction with DVRd rather than VRd (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We administer three to six cycles of DVRd. We then collect stem cells and typically proceed with HCT, followed by maintenance that includes a proteasome inhibitor and <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> until progression. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention and management of complications</strong> – In addition to therapy directed at the malignant clone, the management of most patients with MM includes preventative measures to reduce the incidence of skeletal events  (<a class="graphic graphic_algorithm graphicRef127382" href="/d/graphic/127382.html" rel="external">algorithm 3</a>), thrombosis  (<a class="graphic graphic_algorithm graphicRef122682" href="/d/graphic/122682.html" rel="external">algorithm 4</a>), kidney damage, infections, and neuropathy. (See <a class="local">'Prevention and management of complications'</a> above.)</p><p></p><p class="bulletIndent1">Specific administration considerations, including toxicities and dose adjustments for organ impairment are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011; 117:6063.</a></li><li><a class="nounderline abstract_t">Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016; 127:2955.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol 2016; 34:1544.</a></li><li><a class="nounderline abstract_t">Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014; 28:525.</a></li><li><a class="nounderline abstract_t">Ludwig H, Miguel JS, Dimopoulos MA, et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia 2014; 28:981.</a></li><li><a class="nounderline abstract_t">Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014; 28:269.</a></li><li><a class="nounderline abstract_t">Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 2014; 32:587.</a></li><li><a class="nounderline abstract_t">Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 2020; 136:936.</a></li><li><a class="nounderline abstract_t">Voorhees PM, Sborov DW, Laubach J, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol 2023; 10:e825.</a></li><li><a class="nounderline abstract_t">Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2023.</a></li><li><a class="nounderline abstract_t">Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 2017; 389:519.</a></li><li><a class="nounderline abstract_t">Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22:1582.</a></li><li><a class="nounderline abstract_t">Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012; 119:4375.</a></li><li><a class="nounderline abstract_t">San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359:906.</a></li><li><a class="nounderline abstract_t">Giri S, Grimshaw A, Bal S, et al. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis. JAMA Oncol 2020; 6:1759.</a></li><li><a class="nounderline abstract_t">Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138:176.</a></li><li><a class="nounderline abstract_t">van Rhee F, Szymonifka J, Anaissie E, et al. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood 2010; 116:1220.</a></li><li><a class="nounderline abstract_t">Shaughnessy JD, Zhou Y, Haessler J, et al. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. Br J Haematol 2009; 147:347.</a></li><li><a class="nounderline abstract_t">Mina R, Musto P, Rota-Scalabrini D, et al. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Lancet Oncol 2023; 24:64.</a></li><li><a class="nounderline abstract_t">Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 2008; 140:625.</a></li><li><a class="nounderline abstract_t">Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015; 125:2068.</a></li><li><a class="nounderline abstract_t">Salazar AS, Recinos LM, Mian HS, et al. Geriatric Assessment and Frailty Scores Predict Mortality in Myeloma: Systematic Review and Meta-analysis. Clin Lymphoma Myeloma Leuk 2019; 19:488.</a></li><li><a class="nounderline abstract_t">Stege CAM, Nasserinejad K, Klein SK, et al. Improving the identification of frail elderly newly diagnosed multiple myeloma patients. Leukemia 2021; 35:2715.</a></li><li><a class="nounderline abstract_t">Cook G, Larocca A, Facon T, et al. Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network. Leukemia 2020; 34:2285.</a></li><li><a class="nounderline abstract_t">Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia 2020; 34:224.</a></li><li><a class="nounderline abstract_t">Stege CAM, van der Holt B, Dinmohamed AG, et al. Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities. Leukemia 2020; 34:1964.</a></li><li><a class="nounderline abstract_t">O'Donnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol 2018; 182:222.</a></li><li><a class="nounderline abstract_t">Stege CAM, Nasserinejad K, van der Spek E, et al. Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study. J Clin Oncol 2021; :JCO2003143.</a></li><li><a class="nounderline abstract_t">Musto P, Anderson KC, Attal M, et al. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol 2017; 28:228.</a></li><li><a class="nounderline abstract_t">Facon T, Kumar S, Plesner T, et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med 2019; 380:2104.</a></li><li><a class="nounderline abstract_t">Perrot A, Facon T, Plesner T, et al. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. J Clin Oncol 2021; 39:227.</a></li><li><a class="nounderline abstract_t">Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014; 371:906.</a></li><li><a class="nounderline abstract_t">Hulin C, Belch A, Shustik C, et al. Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. J Clin Oncol 2016.</a></li><li><a class="nounderline abstract_t">Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 2018; 131:301.</a></li><li><a class="nounderline abstract_t">Gay F, Musto P, Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol 2021; 22:1705.</a></li><li><a class="nounderline abstract_t">Palumbo A, Gay F, Cavallo F, et al. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. J Clin Oncol 2015; 33:3459.</a></li><li><a class="nounderline abstract_t">Bringhen S, D'Agostino M, Paris L, et al. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. Haematologica 2020; 105:1937.</a></li><li><a class="nounderline abstract_t">Bonello F, Pulini S, Ballanti S, et al. Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. Cancers (Basel) 2019; 11.</a></li><li><a class="nounderline abstract_t">Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood 2021; 137:3027.</a></li><li><a class="nounderline abstract_t">Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2019; 20:57.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Špička I, Quach H, et al. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. J Clin Oncol 2020; 38:4030.</a></li><li><a class="nounderline abstract_t">Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24:3113.</a></li><li><a class="nounderline abstract_t">Ocio EM, Perrot A, Bories P, et al. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation. Leukemia 2023; 37:1521.</a></li><li><a class="nounderline abstract_t">Goldschmidt H, Mai EK, Bertsch U, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol 2022; 9:e810.</a></li><li><a class="nounderline abstract_t">Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 2019; 394:29.</a></li><li><a class="nounderline abstract_t">Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol 2021; 22:1378.</a></li><li><a class="nounderline abstract_t">Roussel M, Moreau P, Hebraud B, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. Lancet Haematol 2020; 7:e874.</a></li><li><a class="nounderline abstract_t">Gay F, Roeloffzen W, Dimopoulos MA, et al. Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients (abstract 4). Blood 2023.</a></li><li><a class="nounderline abstract_t">Leypoldt LB, Besemer B, Asemissen AM, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. Leukemia 2022; 36:885.</a></li><li><a class="nounderline abstract_t">Leypoldt LB, Tichy D, Besemer B, et al. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma. J Clin Oncol 2024; 42:26.</a></li><li><a class="nounderline abstract_t">Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med 2018; 378:518.</a></li><li><a class="nounderline abstract_t">Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 2020; 395:132.</a></li><li><a class="nounderline abstract_t">Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J 2020; 10:53.</a></li><li><a class="nounderline abstract_t">Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood 2016; 127:2569.</a></li><li><a class="nounderline abstract_t">Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376:2075.</a></li><li><a class="nounderline abstract_t">Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012; 120:9.</a></li><li><a class="nounderline abstract_t">Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012; 120:1589.</a></li><li><a class="nounderline abstract_t">Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011; 118:5752.</a></li><li><a class="nounderline abstract_t">Niesvizky R, Flinn IW, Rifkin R, et al. Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens. J Clin Oncol 2015; 33:3921.</a></li><li class="breakAll">Highlights of prescribing information: Ixazomib. US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208462s012s013lbl.pdf (Accessed on June 03, 2022).</li><li><a class="nounderline abstract_t">Facon T, Venner CP, Bahlis NJ, et al. Oral ixazomib, lenalidomide, and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma patients. Blood 2021.</a></li><li><a class="nounderline abstract_t">Roussel M, Lauwers-Cances V, Wuilleme S, et al. Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Patients, the IFM KRd final results. Blood 2021.</a></li><li><a class="nounderline abstract_t">Jasielec JK, Kubicki T, Raje N, et al. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood 2020; 136:2513.</a></li><li><a class="nounderline abstract_t">Kumar SK, Jacobus SJ, Cohen AD, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2020; 21:1317.</a></li><li><a class="nounderline abstract_t">Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010; 116:5838.</a></li><li><a class="nounderline abstract_t">Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11:29.</a></li><li><a class="nounderline abstract_t">Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86:57.</a></li><li><a class="nounderline abstract_t">Rosiñol L, Oriol A, Mateos MV, et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007; 25:4452.</a></li><li><a class="nounderline abstract_t">Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28:4621.</a></li></ol></div><div id="topicVersionRevision">Topic 6647 Version 82.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21447828" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27002115" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26976420" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24253022" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24177258" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : International Myeloma Working Group recommendations for global myeloma care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23974982" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : IMWG consensus on risk stratification in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24419113" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32325490" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37708911" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38084760" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28017406" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34655533" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22422823" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18753647" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32970151" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17593024" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20501894" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19702643" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36528035" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18302711" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25628469" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31133527" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Geriatric Assessment and Frailty Scores Predict Mortality in Myeloma: Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33589752" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Improving the identification of frail elderly newly diagnosed multiple myeloma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32555295" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31427722" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31969670" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29740809" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33945289" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864218" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Second primary malignancies in multiple myeloma: an overview and IMWG consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31141632" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33326255" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25184863" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27325857" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29150421" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34774221" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26282661" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31582542" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31694338" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33739404" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30559051" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33021870" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16754936" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37316728" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36328040" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31171419" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34529931" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33242444" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients (abstract 4)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34732857" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37753960" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29231133" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31836199" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32393732" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27002117" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21146205" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22498745" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22791289" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21849487" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26056177" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26056177" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33763699" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Oral ixazomib, lenalidomide, and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33827114" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Patients, the IFM KRd final results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32735641" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32866432" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20876454" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19853510" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21181954" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17785704" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20823406" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
